The Impax Patient Assistance Program provides brand name medications at no or low cost and is intended for patients that are uninsured or underinsured. Eligibility for patients with Medicare Part D will be determined on a case by case basis. Income requirements for this program have not been disclosed.
How do I contact Amneal or Impax?
Amneal, Impax and/or Gemini Laboratories Products: Report adverse events, product quality complaints and for medical information inquiries in the United States. Call: (877) 835-5472, option 1 or email: DrugSafety@amneal.com
What is the Patient Assistance Program?
Our patient assistance program is just one of the many ways we help patients in need. Since 2012, our patient assistance program has provided free medicines to thousands of eligible patients.
What is the Amneal Patient Assistance Program?
The Amneal Patient Assistance Program offers eligible individuals the opportunity to apply to receive free medication for up to one year of: RYTARY® (carbidopa and levodopa) and EMVERM® (mebendazole) chewable tablets.
Summary
Thank you for checking into Impax Laboratories, Inc patient assistance program. As of January 24th, 2012 we do not have any specific information related to Impax Laboratories, Inc's program. Please check back regularly as we are updating our database of information daily.
Eligibility
Most programs have income, age, and other eligibility requirements. At this current time we don´t have the eligibility information for Impax Laboratories, Inc's program.
Other Tips
If you have any questions please call the Impax Laboratories, Inc program directly.
Accredited Business
Guarantees that a business meets BBB accreditation standards in the US and Canada.
TopTen Reviews
Highest customer reviews on one of the most highly-trusted product review platforms.
When did Amneal Pharmaceuticals merge with Impax Laboratories?
On May 4, 2018, Amneal Pharmaceuticals and Impax Laboratories combined under one corporate parent,
Where is AMRX traded?
traded on the New York Stock Exchange (NYSE: AMRX).
